23:50 , Jan 3, 2019 |  BC Extra  |  Company News

Management tracks: Barrett joins UroGen

Uro-oncology company UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO. She replaces Ron Bentsur. Last month, Barrett joined the exodus of pharma leaders heading to biotech as she departed Novartis AG (NYSE:NVS;...
19:22 , Dec 14, 2018 |  BC Week In Review  |  Company News

Lilly, AC Immune to develop tau inhibitors

Eli Lilly and Co. (NYSE:LLY) partnered with AC Immune S.A. (NASDAQ:ACIU) to develop the biotech's pipeline of tau aggregation inhibitors, dubbed Morphomers, to treat Alzheimer's disease. The deal includes AC Immune's lead candidate, ACI-3024, which...
11:30 , Dec 12, 2018 |  BC Extra  |  Company News

Lilly, AC Immune to develop tau inhibitors

Eli Lilly and Co. (NYSE:LLY) partnered with AC Immune S.A. (NASDAQ:ACIU) to develop the biotech's pipeline of tau aggregation inhibitors, dubbed Morphomers, to treat Alzheimer's disease. The deal includes AC Immune's lead candidate, ACI-3024, which...
22:45 , Dec 7, 2018 |  BC Extra  |  Company News

AC Immune CSO Muhs passes away

AC Immune S.A. (NASDAQ:ACIU) said CSO Andreas Muhs has passed away after a period of illness. Innovation Fellow David Lowe has been acting as deputy CSO since October, when Muhs began a medical leave of...
20:48 , Oct 23, 2018 |  BC Extra  |  Company News

Management tracks: Celgene, Seres, AC Immune

Celgene Corp. (NASDAQ:CELG) hired Alise Reicin as president of global clinical development, a newly created position. She was SVP and head of global clinical development in R&D at the EMD Serono business of Merck KGaA...
21:56 , Jul 26, 2018 |  BC Extra  |  Company News

Biogen, Eisai AD readout leads to stock dive

Biogen Inc. (NASDAQ:BIIB) sank $39.09 (10%) to $344.74 on Thursday after reporting detailed data from a Phase II trial of Alzheimer's disease candidate BAN2401. Although the data showed that the anti-β amyloid therapy slowed cognitive...
23:25 , Jul 6, 2018 |  BC Extra  |  Financial News

Biotech stocks rise after positive AD data

Biotech indexes gained Friday after Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) reported 18-month data for BAN2401 to treat Alzheimer's disease. Biogen gained $58.67 (20%) to $357.48, adding about $12.3 billion in market cap,...
16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
21:45 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Genentech begins Phase II of AC Immune's anti-Tau mAb for AD

AC Immune S.A. (NASDAQ:ACIU) said the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) started a Phase II trial of Anti Tau mAb (RO7105705) to treat prodromal-to-mild Alzheimer's disease. The trial start triggered a CHF14 million...
03:13 , Jun 9, 2017 |  BC Week In Review  |  Company News

AC Immune, Essex partner to develop undisclosed neurology candidate

AC Immune S.A. (NASDAQ:ACIU) partnered with Essex Bio-Technology Ltd. (HKSE:1061) to develop an undisclosed biologic. The companies said the candidate acts "on a unique neuroprotective mechanism" and will be developed to treat Alzheimer's disease (AD)...